Syncromune®
@syncromuneDeveloping an in situ cancer therapy that combines partial oncolysis and a multi-target biologic drug optimized to treat metastatic solid tumor cancers
Similar User
@UFPathways
@EDohertyGlobal
@kahmari_karen
Visit us at #SITC24 booth #323 for information on our upcoming LEGION-100 Phase 2a trial for metastatic castration-resistant #ProstateCancer!
Syncromune’s Innovative Approach to Solid Tumor Immunotherapy xtalks.com/syncromunes-in… via @xtalks
Get the latest updates on Syncromune's SYNC-T #Cancer Therapy in this @Xtalks interview with Charles Link, M.D. bit.ly/3ASpYkc
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs. #BusinessOfBiotech bioprocessonline.com/doc/drug-deliv…
Syncromune is excited to announce that we have been granted Fast Track designation for our SYNC-T SV-102 for mCRPC therapy! You can read the full press release here: bit.ly/45RRiur and learn more at syncromune.com
@syncromune Syncromune just received fast track designation from the FDA for SV-102!
FGBN News: Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) buff.ly/3xwZbsu #biotech #news
The FDA has granted a fast track designation to SYNC-T SV-102, an investigational combination multi-target immunotherapy for patients with mCRPC. #pcsm #prostatecancer #urology urologytimes.com/view/fda-award…
Great first day at @ASCO #ASCO2024! Stop by our booth #10047 to learn more about our upcoming Phase 1b trial for mCRPC #prostatecancer
Syncromune is excited to announce that we received FDA clearance of our IND application for SYNC-T SV-102! Visit us at booth #10047 at the 2024 @ASCO meeting to learn more about our upcoming LEGION-100 Phase 1b trial for mCRPC. Read the full press release here:…
Syncromune will be in Chicago from June 1-June 3 for the 2024 @ASCO Annual Meeting! Visit us at booth #10047 to learn more about our SYNC-T™ immunotherapy and positive Phase 1 data for mCRPC. Additional details: asco24.myexpoonline.com/exhibitors/exh…
Last month at #AACR24, President and CEO of Lankenau Institute for Medical Research, George Prendergast, Ph.D., spoke with @VJOncology about preclinical modeling of the #SYNCT combination multi-target immunotherapy. View the video interviews here: bit.ly/44lt2QB
In this article titled, “AACR 2024: What Cancer Researchers are Talking About,” @biospace shares some of the hottest topics coming out of the conference, including data from the Phase 1 trial evaluating Syncromune’s SYNC-T therapy in patients with metastatic prostate cancer.…
#ICYMI Positive phase 1 data from the SYNC-T SV-102 trial was recently presented at #AACR24! Dive into the details and join the conversation surrounding these promising results. Click below to catch up on the latest buzz! bit.ly/43TPK1Z
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer ascopost.com/news/april-202… #pcsm #ProstateCancer #immunotherapy #oncology #AACR24 #AACR2024 @AACR
SYNC-T, which combines cryolysis with multitarget immunotherapy, showed clinical activity against mCRPC, according to trial results presented by Charles Link, MD at #AACR24. bit.ly/4aMCFKa @mainlinehealth
Thank you Dr. Charles Link, PhD @syncromune for chatting with us on SYNC-T 85% ORR #ProstateCancer from #AACR24 @AACR Video Coming Soon!
Here at Syncromune we’re developing SYNC-T™, an in situ personalized cancer therapy that is designed to activate T cells and stimulate the immune system to treat metastatic solid tumors where other therapies have failed. Watch our animation to learn more: bit.ly/49e5pdB
We’re pleased to announce that we have been selected for a late-breaking presentation at this year’s #AACR2024. The presentation will feature phase 1 data from studies of SV-102, developed from our SYNC-T Therapy platform. Learn more in our press release: syncromune.com/2024/03/06/syn…
United States Trends
- 1. Thanksgiving 437 B posts
- 2. $CUTO 7.446 posts
- 3. #AskJage N/A
- 4. Custom 72,2 B posts
- 5. Dodgers 59,8 B posts
- 6. UNTITLED UNMASTERED N/A
- 7. #MigglesArmy 3.786 posts
- 8. #WednesdayMotivation 5.418 posts
- 9. #DeFi 26,5 B posts
- 10. SKZ HOP UNVEIL UNFAIR 24,6 B posts
- 11. FELIX UNFAIR MV UNVEIL 24,7 B posts
- 12. Wrecking 15,5 B posts
- 13. DB Cooper 4.367 posts
- 14. Good Wednesday 1.134 posts
- 15. Landman 3.410 posts
- 16. #WednesdayWisdom 1.029 posts
- 17. Dan Crenshaw 3.978 posts
- 18. Sharon Stone 25,8 B posts
- 19. Lake Michigan 2.914 posts
- 20. Section 80 1.285 posts
Something went wrong.
Something went wrong.